Store launching soon — browse the catalog and join the waitlist to be notified at launch.
✦USPS Priority Mail1–3 day delivery across the U.S.Free on orders over $200
Store launching soon — browse the catalog and join the waitlist to be notified at launch.
Your cart is empty
Oral GLP-1 Receptor Agonist
Orforglipron is a synthetic, non-peptide small molecule studied in research as an orally available agonist of the glucagon-like peptide-1 (GLP-1) receptor.
🚀 Launching soon — join the waitlist to be notified when this product is available.
This product is intended strictly for laboratory research use within the United States. It is not approved by the FDA for the diagnosis, treatment, cure, or prevention of any disease. Not for human or veterinary use.
By purchasing, you confirm the material will be used solely for lawful research purposes in accordance with applicable U.S. federal, state, and local regulations.
Orforglipron is a synthetic, non-peptide small molecule studied in research as an orally available agonist of the glucagon-like peptide-1 (GLP-1) receptor.
Laboratory and clinical investigations have examined its receptor-binding behavior and downstream metabolic signaling within controlled experimental frameworks.
Third-party tested for purity, ID, quantity.
Orforglipron (LY3502970) is a non-peptide GLP-1 receptor agonist characterized for oral bioavailability — a property that distinguishes it from peptide-based incretin analogues that require injection. Research has focused on its selective activation of the GLP-1 receptor and the resulting effects on metabolic signaling pathways.
In controlled studies it has been evaluated for receptor pharmacology, glycemic regulation, and body-weight endpoints under structured experimental conditions.
Orforglipron emerged from medicinal-chemistry programs seeking small-molecule alternatives to peptide GLP-1 receptor agonists. Its non-peptide scaffold was designed to retain receptor agonism while enabling oral dosing.
Subsequent phase 1–3 clinical research has characterized its pharmacological profile in type 2 diabetes and obesity research populations.
Investigations into orforglipron focus on GLP-1 receptor activation models and incretin-pathway metabolic regulation. Research frameworks evaluate receptor-binding selectivity, glycemic endpoints, and body-weight outcomes under controlled clinical and preclinical conditions.
No. Eppix Labs products are supplied exclusively for laboratory research. We do not provide dosing, administration, or usage guidance.
Each unit contains the labeled quantity of orforglipron. Independent third-party analysis verifies purity, identity, and net content per batch.
The unit contains only the research compound. Any laboratory materials required for reconstitution or experimental procedures must be sourced separately.
Duration depends entirely on research design, storage conditions, and laboratory protocol.
Orforglipron, an Oral Small-Molecule GLP-1 Receptor Agonist, in Early Type 2 Diabetes
PubMedOrforglipron, an Oral Small-Molecule GLP-1 Receptor Agonist for Obesity Treatment
PubMedThe pharmacological basis for nonpeptide agonism of the GLP-1 receptor by orforglipron
PubMedRelated
Pentadecapeptide studied for angiogenesis signaling, tissue repair pathways, and cellular regeneration research
From$50.00
$60.00
Small molecule studied for metabolic regulation, NAD pathways, and cellular energy signaling
From$40.00
Dual peptide complex studied for actin signaling, tissue regeneration pathways, and recovery system research
From$80.00
Oral peptide format studied for systemic repair signaling and gastrointestinal pathway research
$140.00
